KalVista Pharmaceuticals, Inc.

Ladies and gentlemen, thank you for standing by. Welcome to CalVista Pharmaceuticals operational update and first fiscal quarter financial results. At this time, all participants are in the listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you would need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Ryan Baker, Head of Investor Relations.

Sir, please go ahead.

Thank you, Operator. Good morning, everyone, and thank you for joining us to discuss CalVista Pharmaceuticals Fiscal Year 2026 First Quarter Financial Update and Operating Results. Please note we'll be making certain forward-looking statements today. We refer you to CalVista's SEC filings for discussion of the risks that may cause actual results to differ from the forward-looking statements. On the call with me today from CalVista are Ben Palako, Chief Executive Officer, Nicole Sweeney, Chief Commercial Officer, and Brian Picos, Chief Financial Officer. Dr. Paul Audia, our Chief Clinical Officer, will be joining us for the Q&A portion of the call. Ben will begin with a review of the company's progress during the three months into July 31st, 2025, including FDA approval of Ectorly and other regulatory updates. Nicole will then review the company's commercial progress to date, and Brian will cover the company's financial statements for the most recent quarter. We will then open the call for questions. With that, I will now turn the call over to Ben.